A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

PepGen, a UK-based developed of therapies for Duchenne muscular dystrophy spun out of University of Oxford, has raised $108m in its initial public offering on Nasdaq. The company had raised some $163m in equity funding prior to its flotation from investors including university venture fund Oxford Science Enterprises. Quentic, a Germany-based environmental, social and governance…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.